Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-FcRL5 CAR-T in Relapsed/Refractory Multiple Myeloma
NCT06196255Phase 2Recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Dec 2023
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of FcRL5 CAR-T in multiple myeloma (MM), sponsored by Xuzhou Medical University. Started Dec 2023; status: recruiting.
02
Drugs
FcRL5 CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06196255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196255.